Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study

Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study

Abstract Purpose The antibody–drug conjugate trastuzumab deruxtecan has proven to be not only efficient in patients with HER2+ breast cancers (BC), but also in those patients with so-called HER2-low BC. HER2-low tumors are well described in the general BC population, but not in patients with invasiv...

Full description

Saved in:
Bibliographic Details
Main Authors: Karen Van Baelen, Ha-Linh Nguyen, François Richard, Gitte Zels, Maria Margarete Karsten, Guilherme Nader-Marta, Peter Vermeulen, Luc Dirix, Adam David Dordevic, Evandro de Azambuja, Denis Larsimont, Marion Maetens, Elia Biganzoli, Hans Wildiers, Ann Smeets, Ines Nevelsteen, Patrick Neven, Giuseppe Floris, Christine Desmedt
Format: Article
Language:English
Published: BMC 2025-06-01
Series:Breast Cancer Research
Subjects:
Invasive lobular carcinoma
HER2-low
Clinicopathological features
Survival
Online Access:https://doi.org/10.1186/s13058-025-02058-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13058-025-02058-x

Similar Items